Ovarian Cancer – Geographic Focus: China – Ovarian Cancer – China In-Depth (China)
The ovarian cancer market in China is poised to experience substantial market growth over the 2021-2031 forecast period. For patients with ovarian cancer, chemotherapy regimens remain the go-to option in the first-line setting. The recent approval and launch of PARP inhibitors—Jiangsu HengRui’s fluzoparib and BeiGene’s pamiparib—for later-line treatment has bolstered the treatment armamentarium for metastatic patients. The key driver of market growth will be the anticipated launch and uptake of several targeted therapies for ovarian cancer in China—particularly from PARP inhibitors and immune checkpoint inhibitors—and the incorporation of many of these therapies into China’s National Reimbursement Drug List (NRDL), thereby securing better patient access. Additionally, following the recent reforms in China’s regulatory and reimbursement landscape, manufacturers—both domestic and multinational—will be increasingly incentivized to enter the growing ovarian cancer market.
Questions Answered
- How large is China’s drug-treatable ovarian cancer population, and how will drug-treatment rates change during the forecast period?
- Which are the most commercially relevant drugs in China’s ovarian cancer market and why? What are interviewed experts’ insights into current treatment options?
- What are the market access considerations for key therapies in the ovarian cancer pipeline in China? What sales could they secure in ovarian cancer? What are interviewed experts’ opinions of these therapies?
- What are the key drivers of and constraints in China’s ovarian cancer therapy market, and how will the market evolve over the forecast period?
Content Highlights
Geographies: China.
Primary research: Country-specific qualitative and quantitative insights driven by 5 thought-leader interviews and 75 surveys with medical oncologists. Supported by survey data collected for this and other Clarivate research.
Epidemiology: Diagnosed prevalence of ovarian cancer in urban versus rural China. Clinically and market-relevant drug-treatable populations.
Forecast: 10-year, annualized, drug-level sales and patient share of key ovarian cancer regimens through 2031, based on primary and secondary market research to formulate bottom-up assumptions.
Emerging therapies: Phase III/PR: > 10 drugs; Phase II: 10 drugs; Phase I/II: 7; coverage of select Phase I products.
Product Description
China In-Depth offers comprehensive market intelligence, includingworld-class epidemiology, keen insight into the China-specific A&R environment, current treatment paradigms, in-depth pipeline assessments,and drug forecasts supported by detailed primary and secondary research.This solution helps companies gauge commercial outlooks and optimizeclinical development, subpopulation targeting, physician messaging, andoverall long-term strategy in China.
Table of contents
Ananya Sadhu, Ph.D., Senior Healthcare Research & Data Analyst, China-In-Depth. Dr. Sadhu is a senior analyst on the China-In-Depth team at Clarivate. She has experience in market research and competitive intelligence in various oncology indications and has authored several syndicated reports and forecasts for the pancreatic cancer, gastroesophageal cancer, ovarian cancer, and hepatocellular carcinoma therapy markets. Previously, she was a postdoctoral fellow at the National Centre of Biological Sciences in Bangalore, where she studied the role of chromatin architecture in regulating gene expression in breast cancer. She also worked as a scientific officer at Arvind Remedies, where she coordinated various stages of nonclinical / clinical research activities for the drug development of a patented polyherbal formulation. She holds a Ph.D. in molecular biology from the National Institute of Immunology in New Delhi.